Efficacy and safety of Surufatinib in combination with CAPTEM for patients with advanced G2/G3 NETs: Preliminary results from a single-arm, phase II study

#4002

Introduction: Limited treatment options exist for advanced G2/G3 NETs. Many studies have shown improved efficacy with combined anti-angiogenic therapy and chemotherapy. However, no studies have reported on the use of surufatinib in combination with CAPTEM for NETs.

Aim(s): To assess the efficacy and safety of surufatinib combined with CAPTEM in treating patients with advanced G2/G3 NETs.

Materials and methods: This trial planned to enroll up to 50 patients with advanced G2/G3 NETs who had received ≤3 prior treatments. Patients were given surufatinib 250mg, po, qd, capecitabine 850mg/m2, po, bid, on days 1-14, and temozolomide 200mg/m2, po, qd, on days 10-14, at 28-day cycles until loss of clinical benefit, unacceptable toxicity, or consent withdrawal. The primary endpoint was PFS per RECIST 1.1; secondary endpoints included ORR, DCR, OS, and safety.

Conference:

Presenting Author:

Authors: Wang W, Liu Z, Yang X, Xue Z,

Keywords: g2/g3 nets, surufatinib, captem,